DDAH1 and triple-negative breast carcinoma: In particular, the recent demonstration by our group that DDAH1 inhibition with ZST316 suppresses in vitro vasculogenic mimicry and migration of MDA-MD-231 cells, an established triple-negative breast cancer cell line, warrants the investigation of these effects in xenograft studies.